386
Views
3
CrossRef citations to date
0
Altmetric
Author's View

Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer

Article: e28464 | Received 28 Feb 2014, Accepted 07 Mar 2014, Published online: 15 Apr 2014

References

  • Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H. Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 2014; 192:1286 - 93; http://dx.doi.org/10.4049/jimmunol.1202498; PMID: 24367029
  • Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 2012; 18:2526 - 33; http://dx.doi.org/10.1158/1078-0432.CCR-12-0127; PMID: 22415314
  • Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10:294 - 8; http://dx.doi.org/10.1038/nm999; PMID: 14981514
  • Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008; 68:1563 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-07-5324; PMID: 18316622
  • Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013; 23:516 - 26; http://dx.doi.org/10.1016/j.ccr.2013.03.018; PMID: 23597565
  • Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology 2013; 2:e26677; http://dx.doi.org/10.4161/onci.26677; PMID: 24482750
  • Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18:5212 - 23; http://dx.doi.org/10.1158/1078-0432.CCR-12-1108; PMID: 22837179
  • Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood 2013; 121:1740 - 8; http://dx.doi.org/10.1182/blood-2012-06-436568; PMID: 23305737
  • Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010; 207:2469 - 77; http://dx.doi.org/10.1084/jem.20092450; PMID: 20921286
  • Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, et al, NISC Comparative Sequencing Program. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43:442 - 6; http://dx.doi.org/10.1038/ng.810; PMID: 21499247

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.